ARTA
AKBA icon

A.R.T. Advisors’s Akebia Therapeutics AKBA Stock Holding History

A.R.T. Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-17,353
Closed -$84K – 1406
2019
Q2 		$84K Buy
+17,353
New +$98.7K ﹤0.01% 1214
2018
Q2 		– Sell
-58,371
Closed -$556K – 1389
2018
Q1 		$556K Buy
+58,371
New +$816K 0.02% 912
2017
Q3 		– Sell
-22,770
Closed -$327K – 1326
2017
Q2 		$327K Buy
22,770
+12,500
+122% +$158K 0.02% 977
2017
Q1 		$94K Buy
+10,270
New +$100K ﹤0.01% 1273
2015
Q3 		– Sell
-35,375
Closed -$364K – 1322
2015
Q2 		$364K Buy
35,375
+18,373
+108% +$157K 0.01% 1112
2015
Q1 		$188K Buy
17,002
+6,712
+65% +$71.5K 0.01% 1245
2014
Q4 		$119K Buy
+10,290
New +$148K ﹤0.01% 1294
2014
Q3 		– Sell
-9,246
Closed -$256K – 1281
2014
Q2 		$256K Buy
+9,246
New +$223K 0.01% 1041

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

A.R.T. Advisors's AKBA Position: Q3 2019 in Review

A.R.T. Advisors sold out of Akebia Therapeutics (AKBA) in Q3 2019, closing a stake of 17,353 shares — an estimated $84K sold.

A.R.T. Advisors first reported a position in AKBA in Q2 2014 and held it in 8 quarters. The position peaked at $556K in Q1 2018. 150 funds tracked by Wall St. Rank hold AKBA as of Q3 2019.

  • A.R.T. Advisors reported no remaining Akebia Therapeutics position as of Q3 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 17,353 Akebia Therapeutics shares in Q3 2019, an estimated $84K.
  • A.R.T. Advisors first reported a position in Akebia Therapeutics in Q2 2014 and held it in 8 quarters.
  • A.R.T. Advisors's Akebia Therapeutics position peaked at $556K in Q1 2018.
  • 150 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2019.

Based on A.R.T. Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.